Oramed exits oral insulin, pivots to healthcare investments amid Iran conflict escalation

Filed March 26, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 27, 2025 · ~2 min read

Key Changes

• high

  Sold entire POD oral insulin platform to Lifeward for up to 49.99% equity stake plus warrants and 4% ReWalk revenue share; R&D expenses now borne by Lifeward, not Oramed. Lifeward disclosed substantial doubt about ability to continue as going concern.

  Business: Lifeward transaction verify on EDGAR →
• high

  Invested $38M in Alpha Tau (17% stake, oncology alpha-radiation therapy) and $18M in Nano Dimension (5% stake, activist posture); committed $40M to new VC fund Corner Ally Ventures focused on Israeli tech. Net income of $64M driven by $89M mark-to-market gains on these holdings.

  Business: Alpha Tau, Nano, Corner Ally; MD&A: Financial income verify on EDGAR →
• high

  HTIT joint venture terminated October 2025 after partner failed to meet $60M+ funding commitments; Oramed instead sold OraTech to Lifeward. Planned Nasdaq listing and shareholder spin-off abandoned.

  Business: HTIT termination verify on EDGAR →